Insiders Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 05:10:28 13/03/2026 GMT			5-day change	1st Jan Change
2.110 ^AUD	-1.40%		-8.26%	-22.43%

03-12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
03-11	Mesoblast Appoints Head of Clinical Development, Medical Affairs	MT

Insiders

03-12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
01-02	Mesoblast Limited Announces Changes to Its Board	CI
01-02	Mesoblast Chair Jane Bell to Retire; Successor Named	MT
01-02	Mesoblast Says Chair to Retire, Successor Appointed; Shares Up 3%	MT
01-02	Mesoblast appoints Philip Facchina as non-executive chair	RE
01-01	Mesoblast Limited Announces Changes to Board of Directors	CI
11-17	Mesoblast Appoints James O'Brien CFO	MT
11-17	Mesoblast says James M. O'Brien appointed chief financial officer	RE
11-17	Mesoblast appoints James M. O'Brien as U.S.-based CFO	RE
11-17	Mesoblast Appoints CFO	MT
29/04/25	Mesoblast Limited Appoints Lyn Cobley to Its Board of Directors	CI
23/02/25	Mesoblast Limited Announces Appointment of Dr. Gregory George to its Board of Directors	CI
11/11/24	Longeveron Inc. Appoints Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, Effective December 2, 2024	CI
01/05/24	Mesoblast Limited Announces Board and Committee Changes	CI
22/11/23	Pre-Holiday Data Slew Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Wednesday	MT
03/10/23	Mesoblast Limited Announces Cessation of Michael Spooner as Director	CI
26/09/23	Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee	CI
05/06/23	Mesoblast Limited Appoints Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role	CI
18/08/22	Mesoblast Limited Announces Board Changes	CI
06/04/22	Mesoblast Limited Announces Executive Changes	CI
24/03/22	Mesoblast Limited Appoints Philip R. Krause to its Board of Directors	CI
24/02/22	Donal O'Dwyer Retires from the Board of Mesoblast Limited	CI
02/02/22	Mesoblast Appoints Chief Medical Officer	MT
02/02/22	Mesoblast Names New Chief Medical Officer	MT
01/02/22	Mesoblast Limited Appoints Eric Rose as Chief Medical Officer	CI